PHARMING GROUP NV | 0,072 Euro | 0,000 0 % | |
| WKN: A1H65A ISIN: NL0010391025 Ticker-Symbol: PHGN | Frankfurt | 17.05.13 | 09:02 Uhr |
Branche BiotechnologieAktienmarkt AMX |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 16.05. | Pharming Group N.V.: Pharming reports on financial results first quarter 2013 | 69 | Thomson Reuters ONE | |
| Leiden, The Netherlands, 16 May 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the three months ended 31 March... Mehr lesen zu: Pharming Group N.V.: Pharming reports on financial results first quarter 2013 | ||||
| 19.04. | PHARMING GROUP: CE - Shares - Capital increase | 14 | NYSE Euronext | |
| 17.04. | Pharming, Santarus submit biologics license application for Ruconest | 5 | Pharma Bus Review | |
| 17.04. | Pharming, Santarus Submit RUCONEST Biologics License Application to FDA | 5 | Benzinga.com | |
| 17.04. | Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA | 114 | Business Wire | |
| Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration... Mehr lesen zu: Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA | ||||
| 17.04. | Pharming Group N.V.: Pharming and Santarus announce submission of RUCONEST Biologics License Application to FDA | 66 | Thomson Reuters ONE | |
| LEIDEN, The Netherlands and SAN DIEGO, Calif. (April 17, 2013) -Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) today announced the submission of a Biologics License Application... Mehr lesen zu: Pharming Group N.V.: Pharming and Santarus announce submission of RUCONEST Biologics License Application to FDA | ||||
| 28.03. | Pharming Group N.V.: Pharming announces EMA approval of new manufacturing site for Ruconest® | 87 | Thomson Reuters ONE | |
| Leiden, the Netherlands, March 28th, 2013. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that it has received approval from the European Medicines Agency (EMA)... Mehr lesen zu: Pharming Group N.V.: Pharming announces EMA approval of new manufacturing site for Ruconest® | ||||
| 07.03. | Pharming Group N.V.: Pharming reports on preliminary financial results 2012 | 113 | Thomson Reuters ONE | |
| Leiden, The Netherlands, March 7, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its preliminary (unaudited) financial results for the... Mehr lesen zu: Pharming Group N.V.: Pharming reports on preliminary financial results 2012 | ||||
| 05.03. | PHARMING GROUP: CE - Shares - Capital increase | 28 | NYSE Euronext | |
| 05.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 05.03.2013 - 2 | 101 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 05.03.2013 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 05.03.2013.
INSTR EXCH ISIN INSTRUMENT NAME
FGUB XFRA DE0009763250... Mehr lesen zu: XFRA CAPITAL ADJUSTMENT INFORMATION - 05.03.2013 - 2 | ||||
| 05.03. | XFRA FRA:New Instruments available on XETRA - 05.03.2013-001 | 24 | Xetra Newsboard | |
| The following instruments on XETRA do have their first trading day
05.03.2013
Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am
05.03.2013
TrdMod InstCode Exch ISIN Name... Mehr lesen zu: XFRA FRA:New Instruments available on XETRA - 05.03.2013-001 | ||||
| 04.03. | XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 04.03.2013 | 166 | Xetra Newsboard | |
| The following instruments on XETRA do have their last trading day on
04.03.2013
Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am
04.03.2013
ISIN Name
CA21665V1031 COPPER... Mehr lesen zu: XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 04.03.2013 | ||||
| 04.03. | XFRA 3DG1/DJ5/PHG: AENDERUNG / CHANGE ISIN | 96 | Xetra Newsboard | |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN. WKN UND KUERZEL GEAENDERT. GUELTIG
AB 05.03.2013
FOR THE FOLLOWING INSTRUMENTS ISIN, WKN AND SHORT CODE WILL CHANGE. VALID
FROM MARCH 5, 2013
EINSTELLUNG... Mehr lesen zu: XFRA 3DG1/DJ5/PHG: AENDERUNG / CHANGE ISIN | ||||
| 28.02. | Pharming Group N.V.: Pharming reports on Extraordinary General Meeting | 80 | Thomson Reuters ONE | |
| Leiden, the Netherlands, 28 February 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced that at its Extraordinary General Meeting (EGM) of shareholders... Mehr lesen zu: Pharming Group N.V.: Pharming reports on Extraordinary General Meeting | ||||
| 25.02. | PHARMING GROUP N.V.: CE - Shares - Reverse split | 20 | NYSE Euronext | |
| 04.02. | Pharming Group-Aktie: Das Unternehmen wird Wandelanleihe begeben | 225 | aktiencheck.de | |
| Berlin - Der Analyst von First Berlin, Jens Hasselmeier, bewertet die Aktie der Pharming Group (ISIN NL0000377018/ WKN 915212) nach wie vor mit dem Rating "kaufen".Pharming habe am 16. Januar ein Finanzierungs-Update... Mehr lesen zu: Pharming Group-Aktie: Das Unternehmen wird Wandelanleihe begeben | ||||
| 18.01. | PHARMING GROUP: CE - Shares - Capital increase | 9 | NYSE Euronext | |
| 16.01. | Pharming launches convertible bond | - | StockMarketWire | |
| 16.01. | Pharming Group N.V.: Pharming announces €16.35 million convertible bond financing | 109 | Thomson Reuters ONE | |
| Leiden, the Netherlands, January 16, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has entered into a financing of €16.35 million... Mehr lesen zu: Pharming Group N.V.: Pharming announces €16.35 million convertible bond financing | ||||
| 03.01. | PHARMING GROUP: CE - Shares - Capital increase | 13 | NYSE Euronext | |
